Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS Medicare Rx Price Negotiations Would Fail For Lack Of Force, CMS Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The current Administration, as well as those in the future, would not be willing or able to enforce drug prices significantly below competitive market rates, CMS Chief Actuary Foster says in memo. Giving HHS price negotiating authority would lead to restrictions on drug choice, Administrator McClellan asserts.

You may also be interested in...



HDMA Monitoring Efforts To Repeal Medicare "Non-Interference" Clause

The Healthcare Distribution Management Association is monitoring efforts to reopen the Medicare Modernization Act to remove the clause excluding government from price negotiations, Regulatory Affairs Director Falb noted at the group's distribution management conference. HDMA has also formed a task force to develop proposals for Medicaid reform.

HDMA Monitoring Efforts To Repeal Medicare "Non-Interference" Clause

The Healthcare Distribution Management Association is monitoring efforts to reopen the Medicare Modernization Act to remove the clause excluding government from price negotiations, Regulatory Affairs Director Falb noted at the group's distribution management conference. HDMA has also formed a task force to develop proposals for Medicaid reform.

HHS Negotiating Authority Should Be Medicare Law's Only Change – Kennedy

In a letter to President Bush, Sen. Kennedy (D-Mass.) and Rep. Waxman (D-Calif.) say that giving HHS the authority to negotiate pharmaceutical prices would save $190 bil. over the next decade, with no reduction in benefits.

Topics

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel